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Mycobacterium leprae, the causative agent of leprosy, is unique amongst human
pathogens in its capacity to produce the virulence factor phenolic glycolipid (PGL)-I. In
addition to mediating bacterial tropism for neurons, PGL-I interacts with Complement
Receptor (CR)3 on macrophages (MPs) to promote infection. We demonstrate here
that PGL-I binding to CR3 also enhances bacterial invasion of both polymorphonuclear
neutrophils (PMNs) and dendritic cells (DCs). Moreover, in all cell types CR3 engagement
by PGL-I activates the Syk tyrosine kinase, inducing calcineurin-dependent nuclear
translocation of the transcription factor NFATc. This selectively augments the production
of IL-2 by DCs, IL-10 by PMNs and IL-1β by MPs. In intranasally-infected mice PGL-I
binding to CR3 heightens mycobacterial phagocytosis by lung PMNs and MPs, and
stimulates NFATc-controlled production of Syk-dependent cytokines. Our study thus
identifies the CR3-Syk-NFATc axis as a novel signaling pathway activated by PGL-I in
innate immune cells, rewiring host cytokine responses to M. leprae.
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INTRODUCTION
Leprosy, caused by Mycobacterium leprae (M. leprae) is a chronic infectious disease affecting
primarily vulnerable populations in developing countries, with a global prevalence of
approximately 200.000 in 2016 (1). While consistently provoking skin lesions with sensory loss,
leprosy progression varies extensively across individuals. Patients may develop polar, paucibacillary
(tuberculoid), or multibacillary (lepromatous) forms (LL) of the disease correlating with distinctive
symptoms and immune profiles (2). Multidrug therapy is highly effective at eliminating bacteria
(2). However, treatment often triggers acute inflammatory reactions, such as Type 1 reversal
reactions (T1R), or Type 2 Erythema Nodosum Leprosum (ENL) (2, 3) causing severe nerve
disabilities. In spite of the different clinical presentations, T1R and ENL share biomarkers such
as pro-inflammatory cytokines TNF, IL-1β, or MCP-1 and proteins belonging to the pentraxin
family such as C-Reactive Protein in T1R, or pentraxin-3 during ENL (4) suggesting that common
immune mechanisms underlie leprosy reactions. Multiple knowledge gaps in the pathophysiology
of leprosy still hamper eradication of this complex disease. M. leprae is non-cultivable in vitro,
which is a major hurdle for study of this disease-causing bacterium. Transmission of M. leprae
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remains incompletely resolved and may occur by the respiratory
route rather than direct skin-to-skin contact (5). Susceptibility
to leprosy is controlled by host genetics and several immune-
related candidate genes have been proposed (6). Although
Schwann cells are the preferred host niche for M. leprae,
macrophages (MPs), polymorphonuclear neutrophils (PMNs),
and dendritic cells (DCs) have emerged as key players in shaping
both protective immunity and immunopathology in leprosy
(7). PMNs are a histological hallmark of ENL even though it
remains unclear whether they initiate ENL, or are recruited to
skin lesions in response to inflammation (3). In LL, MPs are
functionally programmed to phagocytose M. leprae whereupon
they transform into foam cells harboring persistent bacilli,
whereas MPs display antimicrobial functions in paucibacillary
patients (8). DCs accumulating in LL lesions secrete IL-10 that
down-modulates T cells (9). Altogether, these findings support
the view that appropriate innate immune responses are critical in
the control ofM. leprae infection.
Pathogenic mycobacteria have evolved sophisticated strategies
to establish chronic infections in humans such as the production
of a diverse array of lipids and glycolipids with virulence
and immunomodulatory properties (10), and M. leprae is
no exception. Phenolic glycolipids (PGLs) are only produced
by mycobacterial species able to persist in the host (11).
M. leprae produces PGL-I (12) whereas PGL-b is produced by
M. bovis, including its derivative the Bacillus Calmette-Guérin
(BCG) vaccine strain. These molecules share a common lipid
backbone and an aromatic nucleus, and are distinguished by
their sugar moiety that confers species-specificity. PGL-I plays
prominent roles in M. leprae virulence: it protects bacilli against
the host bactericidal molecules (13), it allows M. leprae to
colonize peripheral nerves (14), thus damaging them (15), and
manipulates the host immune response to the bacterial benefit
(16). Using an original approach of genetic reprogramming to
produce rBCG::PGL-I as a cultivable surrogate of M. leprae,
we previously reported that PGL-I targets the lectin domain of
Complement Receptor (CR) 3—or integrin αMβ2—to improve
bacterial entry into human MPs (17). PGL-I expression also
down-regulates the production of NF-κB-dependent cytokines
by human MPs, through direct interaction of its trisaccharide
domain with Toll-like receptor (TLR) 2 (18). We also observed
that PGL-I impaired TRIF-dependent TLR4 signaling, decreasing
induction of iNOS in activated MPs (19). While physiologically
relevant MPs only represent one arm of the first line of
defense against invading M. leprae. Our finding that PGL-I
promotes CR3-dependent uptake by MPs suggests that other
CR3-expressing cells, such as DCs and PMNs (20), are susceptible
to M. leprae infection. In the present study, we conducted
parallel investigations in primary MPs, DCs, and PMNs to
gain an integrated view of PGL-I’s impact on the innate
immune response. Taking advantage of the three cultivable
genetically reprogrammed BCG strains (17) that only differ
by the ectopic expression—or deletion—of the PGL molecule,
we highlight a powerful mechanism of immune deviation
evolved by M. leprae, as CR3 targeting by PGL-I confers the
pathogen with capacity to invade and modulate the cytokine
responses of the three cell types. Furthermore, it revealed a
novel signaling axis connecting CR3-mediated phagocytosis with
Syk-calcineurin-NFAT signaling, bringing a new dimension to
immunoregulation in infectious diseases, while providing novel
targets for therapeutic intervention in leprosy.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Construction of the recombinant strains rBCG::noPGL,
rBCG::PGL-b, rBCG::PGL-I have been described previously
(17, 21). The various recombinant strains were transformed with
plasmid pWM124, a mycobacterial replicative plasmid carrying
the gfp gene under the control of the pblaF∗ promotor (17).
Strains were cultured in Middlebrook 7H9 broth (Invitrogen,
Cergy-Pontoise, France) containing 0.05% Tween 80 (Sigma-
Aldrich, St. Louis, USA) and ADC (5% BSA fraction V, 2%
dextrose, 0.003% beef catalase and 0.85% NaCl; BDMicrobiology
Systems) and supplemented with 40µg/ml of Kanamycin sulfate
(Sigma-Aldrich, St. Louis, USA) or 50µg/ml of Hygromycin
B (Sigma-Aldrich, St. Louis, USA) for the fluorescent strains.
Ten days before infection, bacteria were inoculated into 7H9
with ADC without Tween 80. Bacteria were pelleted at 3,000× g
10min, washed and suspended in PBS. Clumps were dispersed by
vortex with 4mm diameter glass beads. Bacteria were centrifuged
(200× g) for 5min and concentration of bacterial suspensions
was measured by OD 600 nm (1 OD = 108 bacilli/ml). To assess
CFUs, serial dilutions were plated on Middlebrook 7H11 agar
plates supplemented with OADC (ADC supplemented with
0.05% oleic acid).
Mouse Lines, Ethics Statement and
Treatments
Six- to eight-week-old C57BL/6 male mice were obtained from
SAS Janvier (Le Genest Saint Isle-France); itgam−/− mice were
kindly donated by Alain Bessis, and myd88−/− mice were
bred at Plateforme Infectiologie Experimentale (PFIE, U1277,
INRA, Center Val de Loire). Before experiments, all mice were
reared at the PFIE in the specific pathogen-free resident animal
facility. All animal studies were approved by the “Val de Loire”
Ethics Committee for Animal Experimentation (CEEA VdL)
and was registered by the French National Committee for
Animal Experimentation.
Mouse Infection
Mice anesthetized by i.p. injection of ketamine/xylazine cocktail
received 5 × 106 CFUs of rBCG::PGL-I or rBCG::noPGL under
20 µL in each nostril. Mice received 40 µL of vehicle (DMSO
2%), or 1µM Syk inhibitor (GS-9973, ApexBio Technology),
or 50 ng/ml NFATc inhibitor (Cyclosporin A, Cell signaling
Technology) via the nasal route 1 h before and 1 h after
BCG infection. Mice were euthanized 24 h post-infection by
CO2 inhalation.
PGL-I Binding to Immobilized Receptors
and Competition Experiments
Experiments were performed as described (18). Briefly,
recombinant mouse or human CR3 (1 µg/well, R&D Systems)
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were coated on 96-well MaxiSorpTMELISA plates (Nunc)
overnight at 4◦C. Purified, native PGL-I (BEI Resources, NIAID,
NIH) was dissolved in ethanol After washing and blocking,
specified concentrations of PGL-I diluted in binding buffer were
added to the wells and incubated at 37◦C for 1 h. Bound PGL-I
was detected by an indirect method using an anti-PGL-I antibody
(Ab SC-48, BEI Resources, NIAID, NIH), followed by addition
of a secondary horseradish peroxidase (HRP)-coupled goat
anti-mouse Ab (BioRad). HRP activity, corresponding to bound
PGL-I, was determined by reading the absorbance at 450 nm.
For competition assays, purified native PGL-I diluted in ethanol
(500 ng/well) was added to 96-well PolySorpTM ELISA plates
(Nunc). After evaporation, washing and blocking, recombinant
mouse CR3 (500 ng/well) was incubated with 50µM of synthetic
oligosaccharide domains of PGL-b and PGL-I (18), for 1 h at
37◦C. CR3 binding to PGL-I coated to the plates was performed
as above and bound CR3 was detected by an indirect method
using anti-CD11b Ab (2LPM19c, Santa Cruz Biotechnology).
Bone Marrow and Lung Cells Preparation
Femurs and tibias were harvested from 6-week-old (WT,
itgam−/− or myd88−/−) mice reared at PFIE animal facility.
Bones from phagocyte-specific clec7a−/− mice (line LysM-
Cre/Dectin-1L2/L2 (22) were also kindly donated by Agnes Coste
and those fromMRP8-Cre+Sykflox/flox and LysM-Cre+Sykflox/flox
by Attila Mocsai (23). Bone marrow-derived cells were obtained
as previously described (24). Briefly, DCs were obtained with
1% supernatant from the J558 cell line producing murine
granulocyte-macrophage colony-stimulating factor, and MPs
were obtained after culture with 30% L929 cell-conditioned
medium as a source of macrophage colony-stimulating factor.
Two passages were performed in presence of 100U penicillin
and 100µg/ml streptomycin (Gibco). Cells, used at day 10 for
infectivity and cytokine assays, were suspended in complete
medium without antibiotics. PMNs were directly purified from
bone marrow by magnetic positive selection. Cells suspended
in PBS/0.5% FCS were incubated 15min with purified anti-Ly-
6G PE-conjugated antibody (clone1A8, BD Biosciences) followed
by 15min with anti-PE magnetic beads (Miltenyi Biotec). More
than 95% pure PMNs were obtained as assessed by microscopy
after May-Grünwald-Giemsa staining. Viability by trypan blue
exclusion was 98%. Lung cells were collected as previously
described (25). Briefly, euthanized mice (n = 11–12) were
perfused with PBS and lung tissues were digested for 1 h with
collagenase D (5 mg/ml, Roche) and DNAse A (40 U/ml, Roche)
before filtering cells through 100µM nylon cell strainer (BD
Falcon). For BAL cells and fluid collection, four washes of
the lungs with 0.5ml of cold PBS were performed through
cannulated trachea. The first wash was used to measure cytokine
while the three other washes were pooled to prepare single cell
suspensions that were kept at 4◦C until FACS staining. In order
to get enough material, BAL was performed on 12 animals of
each group and two were pooled (n = 5–6). For FACS staining,
cells were incubated 20min with 2% total mouse serum, and
then labeled in PBS supplemented with 5% FCS and 0.1% total
mouse serum with antibodies against the surface markers CD11b
(clone M1/70), Ly6G (clone 1A8), Ly 6C (clone AL-21), all from
BD Biosciences.
Infectivity, Cytokine Assays and Gene
Expression Quantification
DCs, PMNs and MPs were infected with rBCG::PGL-I,
rBCG::PGL-b, or rBCG::noPGL at MOI of 5 for 2 h at
37◦C. As indicated, bacteria were opsonized with 2% of fresh
mouse serum and/or 1µM Syk inhibitor GS-9973 (ApexBio
Technology), 1 or 50 nM of Cytochalasin D (Sigma Aldrich),
were added 1 h before infection. After three washes in PBS,
cells were lysed with PBS containing 0.05% Triton X-100
for 15min. Dilutions were plated on Middlebrook 7H11 agar
supplemented with OADC and CFUs were counted 2–3 weeks
later. For cytokine assays, cells were infected as indicated
above. After 2 h contact and washes, cells were incubated
overnight in complete medium (RMPI, 10% FCS, L-Glutamine).
Cells were also stimulated with γ-irradiated M. leprae, strain
NHDP (BEI Resources, NIAID, NIH) equivalent to MOI 10.
To analyze role of the different signaling pathways, cells were
treated 1 h before infection with inhibitors of Syk (1µM of GS
99-73); NFATc (500 pg/ml of FK506-tacrolimus or 50 ng/ml of
cyclosporin A; Cell signaling technology); phagocytosis (1 nM
or 50 nM of Cytochalasin D). Control wells received DMSO
vehicle alone. When indicated, CR3 was blocked by incubating
cells for 1 h with 150 µg of anti-CD11b antibody (clone
M1/70, BD Biosciences), or Rat IgG2b,κ isotype. Cell culture
supernatants were harvested 16–20 h later and cytokines were
measured by ELISA with kits (R&D Systems) according to
manufacturer’s instructions.
WT or itgam−/− MPs were infected for 2 h at MOI 5 with
the three rBCG strains and total RNA were extracted with the
NucleoSpin RNA II kit (Macherey-Nagel). After removal of
residual genomic DNA with RNase-free DNase (Macherey-
Nagel), RNA quantity and integrity were measured with
NanoDrop spectrophotometer (NanoDrop Technologies). Total
RNA (1 µg) was reverse transcribed to cDNA using random
hexamers and iScript reverse transcription supermix (Bio-Rad)
according to the manufacturer’s instructions. qRT-PCR was run
with iQ SYBRGreen Supermix (Bio-Rad) in a LightCycler R©
480 System apparatus (Roche). Reaction mix consisted of
1:10 diluted cDNA in 5 µl nuclease-free water, 300 nM each
forward and reverse primer for il-1β (for TCTAATGCCTTC
CCCAGGGC; rev GACCTGTCTTGGCCGAGGAC) and the
three house keeping genes hprt1 (for CAGTCCCAGCGT
CGTGATTA; rev TGGCCTCCCATCTCCTTCAT) rpl4 (for
GACCAGTGCTGAGTCTTGGG; rev GTATTCACTCTG
CGGTGCCA) and ppia (for GCTGGACCAAACACAAACGG;
rev CCAAAGACCACATGCTTGCC) and iQ SYBRGreeen
Supermix (Bio-Rad) in a total reaction volume of 15 µl.
After 45 cycles of amplification 45 cycles (95◦C 5 s; 62◦C 5 s)
quantification was performed with Bio-Rad Laboratories CFX
Manager software. 1Cq values between il1b and mean of the
three reference genes were calculated as 1Cq = Cq[il1b]-mean
Cq[hprt1, ppia, rpl4] to normalize gene expression and11Cq values
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were calculated between each sample and control as 11Cq
= 1Cq[infected cells]- 1Cq[mock−infected] cells. Data were then
expressed as RQ= 2−11Cq.
NFATc Translocation Analysis
MPs derived from bone marrow of WT or itgam−/− mice were
seeded on 24-well plate coverslips. Adherent cells were infected
with rBCG::PGL-I or rBCG::noPGL at MOI 5 for 30min at
37◦C. Cells were fixed in 4% PFA for 20min. After saturation
in D-PBS- BSA with 5% for 30min, cells were labeled with
anti-NFATc2 antibody (clone 25A10.D6.D2, Invitrogen) in PBS
containing 0.1% Triton X-100, for 1 h at room temperature. After
washings in PBS with 0.001% Triton X-100, cells were incubated
with Alexa 633-conjugated goat anti-mouse IgG1 antibody
(Invitrogen) for 1 h at room temperature. Slides were mounted
with Fluoromount-G medium containing DAPI (Invitrogen).
Images were captured with a confocal Leica TCS SP8microscope.
NFATc translocation was quantified by calculating the Manders
coefficient using the JaCOP plugin (26) for Image J.
Statistical Analysis
Data were expressed as arithmetic mean ± standard error
of the mean (SEM). Statistical analyses were performed with
Prism 4.0 software (GraphPad) and R software (3.4.1 version,
Rcmd pluging). Analyzes were performed on data from 2 to
5 independent experiments. Paired non-parametric two-tailed
K-Sample Fisher-Pitman Permutation test was used to analyse
data, with a Monte Carlo resampling approximation, except for
Figure 4E where Mann-Whitney t-test was applied. Represented
p-values are: ∗p< 0.05; ∗∗p< 0.01, and ∗∗∗p< 0.001.
RESULTS
CR3 Targeting by PGL-I Allows Broad and
Efficient Invasion of Innate Immune Cells
We used three genetically engineered BCG strains,
reprogrammed to either keep the native PGL-b molecule
fromM. bovis (rBCG::PGL-b), replace it by PGL-I fromM. leprae
(rBCG::PGL-I), or lack expression of any PGL (rBCG::noPGL)
(17). Modified BCGs grew comparably and, with the exception
of PGL, exhibited a similar envelope (17, 18), making them
physiologically relevant tools to dissect the specific role of M.
leprae PGL-I in mycobacterial interaction with the host. We
first compared the infectivity of rBCG::noPGL, rBCG::PGL-
b, and rBCG::PGL-I in mouse bone marrow-derived DCs,
PMNs and MPs under non-opsonic conditions mimicking
primary infection. While rBCG::PGL-b and rBCG::PGL-I both
infected the three cell types more effectively than rBCG::noPGL,
PGL-I clearly conferred BCG with the highest infectivity
(Figure 1A). Since we were interested in the role of CR3 (17),
we next analyzed the impact of opsonizing the strains on their
phagocytosis. Treatment with fresh serum from naïve mice
increased infectivity of all strains to similar levels (Figure 1B).
Ratios of bacteria recovered from DCs, PMNs and MPs after
infection under non-opsonic conditions vs. serum-opsonizing
conditions were around 50% and 20% for rBCG::PGL-b and
rBCG::noPGL, respectively (Figure 1C), illustrating the gain
conferred by complement opsonization for these two strains.
Notably, in all cell types, non-opsonized rBCG::PGL-I infectivity
was close to 90% as compared to opsonizing conditions
(Figure 1C), emphasizing the role of PGL-I in promoting
phagocytosis in all environments and conditions. We previously
showed that purified PGL-I efficiently binds human CR3 via
its lectin domain (18). Here, we confirmed that PGL-I also
bound the mouse counterpart (Figure 1D). Using chemically
synthesized oligosaccharide domains of the molecules (18),
we observed that PGL-I binding to CR3 was competed out by
PGL-I and not PGL-b sugar moiety (Figure 1E) indicating the
specificity of the lectin domain of CR3 for the M. leprae-specific
saccharidic moiety of PGL-I. To evaluate the importance of
CR3-mediated phagocytosis in each cell type, we then used bone
marrow cells derived from itgam−/− mice, which are defective
for expression of the CD11b chain in the CR3 heterodimer (27).
As compared to their WT counterparts, strain infectivity was
decreased in CR3-deficient cells whatever the cell type. This was
observed for all strains albeit to different degrees (Figure 1F).
Remarkably, infectivity of rBCG::PGL-I was the most affected,
with only approximately 10% of bacteria recovered from CR3-
deficient cells, as compared to WT (Figure 1G). On the contrary,
even though rBCG::noPGL infectivity was less than rBCG::PGL-I
in WT cells, half of the bacilli were still recovered from CR3-
deficient cells as compared to WT. Therefore, as also found with
human MPs (17), production of PGL-I allows mycobacteria to
target the CR3 lectin site through its oligosaccharide moiety of
the molecule for optimal invasion of DCs and PMNs.
CR3-Mediated Phagocytosis of PGL-I
Expressing Mycobacteria Requires Syk
We observed that rBCG::PGL-I infectivity was equally important
in opsonized and non-opsonized conditions. The Syk pathway
being critical for initiating CR3 integrin signaling (28) and
for phagocytosis of opsonized particles (29), we next asked if
Syk was involved in effective internalization of rBCG::PGL-
I under non-opsonic conditions. Bone marrow-derived DCs,
PMNs and MPs were incubated with rBCG::noPGL, rBCG::PGL-
b and rBCG::PGL-I in the presence of GS-9973, a selective
inhibitor of Syk (30). Syk inhibition reduced the infectivity of all
strains into each cell type (Figure 2A). However, this decrease
was significantly more important for rBCG::PGL-I, with only
10% of bacteria recovered under Syk inhibition as compared
to ∼30–50% with rBCG::PGL-b and rBCG::noPGL, respectively
(Figure 2B). Interestingly, Syk inhibition and CR3 deficiency
induced comparable reduction of rBCG::PGL-I phagocytosis
(Figures 1F, 2B). Together, our data thus suggested that
Syk critically contributes to the non-opsonic, CR3-mediated
phagocytosis of rBCG::PGL-I. Under non-opsonizing conditions,
Syk-engagement is well-documented for phagocytosis involving
C-type Lectin Receptors (CLRs) other than CR3. For instance
Dectin-1 (CLEC7A) (31), which is expressed by DCs, PMNs,
and MPs (32), mediates phagocytosis of fungal pathogens via the
Syk pathway. Mycobacteria also activate Dectin-1, even though
they do not produce β-glucans (33). To evaluate the potential
contribution of Dectin-1, we compared infectivity of the three
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FIGURE 1 | Targeting of the lectin domain of CR3 by rBCG::PGL-I allows efficient infection of innate cells. (A,B) Number of CFUs recovered from bone
marrow-derived DCs, PMNs and MPs after 2 h infection with rBCG::noPGL, rBCG::PGL-b, or rBCG::PGL-I at MOI of 5 under serum-free conditions (A, n = 8), or after
30min complement opsonizing with fresh mouse serum before contact with the cells (B, n = 4). (C) Ratio of CFUs recovered for the three strains under
non-opsonizing versus opsonizing conditions. (D) Binding of purified native PGL-I to recombinant human or mouse CR3. Absorbance values obtained after indirect
ELISA with anti- PGL-I antibodies and determination of the dissociation constant Kd (n = 6). (E) Competition assay measuring binding of recombinant mouse CR3 to
purified PGL-I in presence of the chemically synthesized oligosaccharide domains of PGL-b or PGL-I. Absorbance reveals bound CR3 measured by indirect ELISA
with anti-CR3 antibodies (n = 3). (F) Number of CFUs determined as in (A) for the thee strains after infection of DCs, PMNs or MPs derived from wild-type (WT) mice
or itgam−/− mice deficient in CR3 (n = 10). (G) Ratio of CFUs recovered from itgam−/− vs. WT cells in the three cell types for the three strains (n = 10). Data are
presented as mean ± SEM. **P < 0.01; ***P < 0.001.
rBCG strains in DCs, MPs, and PMNs from mice bearing
selective disruption of the clec7a gene in myeloid cells (22),
itgam−/− and WT mice (Figure 2C). Compared to WT, Dectin-
1-deficient cells displayed a comparable decrease in infectivity
of the three BCG strains irrespective of their PGL production
(Figure 2D). Moreover, infectivity loss of rBCG::PGL-I was less
important than in CR3-deficient cells. We conclude that contrary
to CR3, Dectin-1 mediates BCG phagocytosis independently
of PGL production. Notably, CR3-mediated phagocytosis of
rBCG::PGL-I required the Syk pathway in all cell types. Even
though Syk-dependent Dectin-1—and possibly other CLRs
(34)—cooperated with CR3 for efficient rBCG::PGL-I entry, they
did not compensate for the absence of CR3.
CR3-Mediated Infection by rBCG::PGL-I
Selectively Induces Syk-Dependent
NF-κB-Independent Cytokines
In response to mycobacteria, Syk participates to pro-
inflammatory cytokine gene transcription via activation of
the canonical NF-κB pathway in response to various CLR stimuli
(33). This pathway, which engages CARD9/Bcl-10/MALT1,
comes in addition to classical MYD88-dependent activation
of NF-κB that is efficiently triggered by a range of TLR
mycobacterial ligands (35). Since Syk was essential for CR3-
mediated infection (Figure 1), we tested if PGLs activated
Syk-mediated signaling pathways, using NF-κB-dependent
and independent cytokines as readouts. As expected in all
conditions tested, cells incubated with medium or vehicle
alone did not produce appreciable amounts of cytokines
(Supplementary Figure S1). After overnight infection,
all cell types produced comparable amounts of NF-κB-
dependent cytokines, namely TNF (Figure 3A) IL-6 or IL-12p40
(Supplementary Figures S2A,B), whatever the rBCG strain used
for stimulation. To our surprise, we did not detect any significant
reduction of TNF production by cells derived from itgam−/−
mice or by WT cells treated with Syk inhibitor (Figure 3A).
Therefore, despite being crucial for CR3-mediated infection, Syk
signaling did not modify the induction of NF-κB-dependent pro-
inflammatory cytokines. Syk activation stimulates the production
of other cytokines, such as anti-inflammatory IL-10 in PMNs
(36), IL-2 in DCs (37), or IL-1β in MPs (38) (Figure 3B). Notably
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FIGURE 2 | The Syk pathway regulated by CR3 engagement controls infection by rBCG::PGL-I (A) Number of CFUs recovered as in Figure 1A from DCs, PMNs, or
MPs that were treated with vehicle or 1µM of Syk inhibitor GS-9973, 1 h before infection with the rBCG strains (n = 6). (B) Ratio of CFUs recovered from cells treated
with the Syk inhibitor vs. vehicle for the three strains and cell types. (C) Number of CFUs recovered as in Figure 1A from DCs, PMNs or MPs derived from bone
marrow of WT or itgam−/− or clec7a−/− mice harboring the dectin-1 deficiency specifically in myeloid cells (22) (n = 4). (D) Ratio of CFUs from clec7a−/− vs. WT cells
for the three strains and cell types. Data are presented as mean ± SEM *P < 0.05; **P < 0.01.
the production of such cytokines was significantly enhanced
by infection with rBCG::PGL-I, compared to the other strains.
We measured 2.6-fold more IL-2 produced by DCs, 4.1-fold
more IL-10 by PMNs and 4.0-fold more IL-1β by MPs, as
compared to rBCG::noPGL. Interestingly, enhanced production
of these cytokines was lost in cells derived from itgam−/−, or in
WT cells treated with Syk inhibitor (Figure 3B and Table S1A).
In order to rule out potential off-target effects of the Syk inhibitor,
we used bone-marrow PMNs from MRP8-Cre+Sykflox/flox mice
(23) and MPs from LysM-Cre+Sykflox/flox mice (23) where
Syk was cell-specific depleted. Similar dramatic decrease of
IL-10 production by PMNs and IL-1β by MPs was observed
in response to rBCG::PGL-I in WT cells treated with the Syk
inhibitor and in Syk-deficient cells as compared to controls
(Supplementary Figure S2C). In MPs, IL-1β is produced under
immature form and is then cleaved by the inflammasome (39).
We measured if Syk inhibition or CR3 deficiency had any
impact on pro-IL-1β gene transcription in MPs. We observed
higher levels of pro-IL-1β mRNA synthesis by MPs infected
with rBCG::PGL-I as compared to the two other strains. In
CR3-deficent MPs or in WT MPs treated with the Syk-inhibitor,
pro-IL-1β was reduced (Supplementary Figure S2D) suggesting
that IL-1β secretion by MPs by CR3/Syk was regulated at the
transcriptional level. The Syk-dependent NF-κB-independent
cytokine signature was decreased in Dectin-1 deficient cells as
compared to WT, but this was independent of PGL production.
On the contrary, this signature was profoundly reduced in
cells derived from itgam−/− mice in response to rBCG::PGL-I
with only 27% of IL-2 produced by DCs, 15% of IL-10 by
PMNs and 18% IL-1β by MPs, as compared to WT controls.
Of note, Syk inhibition produced the same effects as CR3
deficiency (Figure 3B). By contrast, even though rBCG::noPGL
induced lower levels of the three cytokines, CR3 loss or Syk
inhibition only reduced their production by half (Table S1A).
Therefore, although the Syk pathway could be activated by all
strains through Dectin-1, and likely other CLRs (33), maximal
production of Syk-dependent NF-κB-independent cytokines
observed after infection by rBCG::PGL-I required CR3. For
their part, pro-inflammatory cytokines triggered by CARD9/Bcl-
10/MALT1 below Syk (33) were not impacted by CR3-mediated
infection with rBCG::PGL-I.
PGL-I-Driven Activation of Syk Triggers
Nuclear Factor of Activated T-Cells Nuclear
Translocation in Innate Cells and Rewires
the Immune Response
Upon recognition of particulate β-glucans by Dectin-1, MPs,
and DCs form a phagocytic synapse that activates a signaling
cascade involving Syk, calcineurin and Nuclear Factor of
Activated T-cells (NFATc) (40). Nuclear translocation of NFATc
triggers a specific gene expression program in PMNs and
DCs contributing to control fungal infections (41, 42). Having
shown that rBCG::PGL-I infectivity was Syk-dependent, we
asked if CR3 targeting by PGL-I impacted Syk signaling
through the calcineurin-NFATc pathway. We first tested the
importance of phagocytosis (40) in this process, by treating
cells with the actin polymerization inhibitor cytochalasin D
(CytoD) prior to infection with our BCG strains. This treatment
had no significant impact on the production of IL-12p40 or
TNF (Supplementary Figures S3A,B). On the contrary, CytoD
induced a dose-dependent reduction of IL-2 production by DCs,
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FIGURE 3 | CR3-mediated infection by rBCG::PGL-I induces Syk-dependent NF-κb independent cytokines. (A) TNF produced in supernatants of DCs, PMNs or MPs
derived from bone marrow of WT mice, treated with DMSO (vehicle), or 1µM of the Syk inhibitor GS-9973, and itgam−/− mice was determined by ELISA after
overnight infection with the three rBCG strains at MOI of 5 under non-opsonizing conditions (n = 8). (B) IL-2 produced by DCs, IL-10 by PMNs and IL-1β by MPs from
WT cells treated with DMSO, or 1µM of the Syk inhibitor GS-9973 or itgam−/− or clec7a−/− cells infected as in (A) were determined by ELISA (n = 4). Data are
presented as mean ± SEM. **P < 0.01; ***P < 0.001.
IL-10 by PMNs and IL-1β by MPs (Figure 4A) in response to
infection by all rBCG strains. The highest dose of CytoD most
dramatically impacted production of cytokines by rBCG::PGL-
I infected cells that produced only between 8 and 17% of the
amount as compared to vehicle-treated cells, depending on
the cell type (Table S1B). This showed that phagocytosis, most
efficiently induced by rBCG::PGL-I, was necessary for induction
of Syk-dependent NF-κB-independent cytokines. Phagocytosis of
particulate β-glucans via Dectin-1 results in calciummobilization
downstream of Syk, which triggers calcineurin-dependent NFATc
translocation to the nucleus. NFATc activation is key to instruct
IL-2 production by DCs (43). Treatment with NFATc inhibitors
cyclosporine A (CsA), or tacrolimus (FK506) reduced the Syk-
dependent NF-κB-independent cytokine signature whatever the
strain used (Figure 4B and Table S1B). Both treatments most
dramatically impacted cytokine production by rBCG::PGL-I
infected cells that only retained between 12 and 25% of the
amount produced by vehicle-treated controls depending on the
cell type (Figure 4B and Table S1B). Another important player
in bacterial-induced inflammation is Prostaglandin E2 (PGE2)
(44). It is produced following transformation of arachidonic acid
by Cyclooxygenase (COX) enzymes. Transcription of inducible
COX-2 is under the control of NFATc (45) and as a consequence,
the highest production of PGE2 by DCs, PMNs, or MPs was
observed in response to rBCG::PGL-I infection. In cells derived
from itgam−/−, PGE2 production was reduced, as compared to
WT. In absence of CR3, MPs produced similarly low amounts of
PGE2 whatever the BCG strain used (Figure 4C). Therefore, in
addition to the cytokine signature being under the regulation of
NFATc, PGE2 that plays important roles in leprosy (14, 46), was
also highly induced by rBCG::PGL-I engaging CR3.
We then analyzed by confocal microscopy NFATc
translocation to the nucleus of MPs derived from WT or
itgam−/− mice (Figure 4D). Shortly after incubation with
rBCG::PGL-I we observed localization of NFATc2 to the
nucleus in 55% of WT MPs, whereas nuclear translocation was
only detected in 25% of itgam−/− MPs, a level comparable
to that observed in WT MPs infected with rBCG::noPGL
(Figure 4E). To see if the immunomodulatory properties of
rBCG::PGL-I were conserved for native M. leprae, we tested if
myeloid cells produced Syk-dependent cytokines in a similar
way (Figure 4F). As for rBCG::PGL-I, the three cell types
all produced the three signature cytokines after M. leprae
stimulation. Moreover, CR3 deficiency and Syk or NFATc
inhibition reduced IL-2 by DCs; IL-10 by PMNs and IL-1β by
MPs to similar extents after stimulation with M. leprae or its
surrogate rBCG::PGL-I (Table S1C). Thus, CR3 targeting by M.
leprae PGL-I signals through Syk/calcineurin/NFATc to induce a
specific mediator signature.
Syk/calcineurin/NFATc Is the Preferred
Pathway Triggered by rBCG::PGL-I to
Rewire Innate Cells
NFATc activation triggered by Dectin-1 in response to particulate
β-glucans is not connected to TLR activation (41, 43).
However, MYD88 seems crucial for IL-10 production by
mycobacteria-infected PMNs (36). We queried then if MYD88
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was compulsory for production of the Syk/calcineurin/NFATc
cytokine signature downstream of CR3. In agreement with Zhang
et al. (36), MYD88-deficient PMNs produced less IL-10 thanWT,
irrespective of the strain used for infection. We also observed
that MYD88-deficient DCs produced less IL-2, as compared to
WT (Figure 5A). MYD88−/− cells infected with rBCG::noPGL
produced minimal levels (Supplementary Figure S3C), even
though amounts were above the background measured in cells
with medium alone (Supplementary Figures S1D,E). On the
contrary, rBCG::PGL-I infected MYD88−/− cells retained 27%
of IL-2 (DCs), or 44% of IL-10 (PMNs) production, as compared
to their WT counterparts (Figure 5A). As expected, production
was reduced to minimal levels (i.e., similar to rBCG::noPGL-
infected MYD88−/− cells) when Syk or NFATc translocation was
blocked (Figure 5A). This showed that Syk-dependent NFATc
translocation upon rBCG::PGL-I targeting of CR3 did not
depend on MYD88 to induce the specific cytokine signature.
We then blocked CR3 or NFATc translocation in rBCG::PGL-I-
infected WT and MYD88-deficient cells. In both case, cytokine
production was reduced to the minimum levels observed
with rBCG::noPGL infected MYD88-deficient cells (Figure 5B)
indicating that the MYD88 pathway was not able to rescue
the Syk/NFATc pathway when the mycobacterium producing
PGL-I targeted CR3. This clearly showed that CR3/Syk/NFATc
was preferentially triggered by rBCG::PGL-I independently of
MYD88, even though the two pathways cooperated to induce
maximum levels of the signature cytokines.
CR3 Targeting by PGL-I Signals Through
Syk/NFATc in vivo
To confirm that PGL-I also targeted CR3 in vivo, we infected
WT or itgam−/− mice with rBCG::PGL-I. Fluorescent versions
of rBCG::PGL-I, and rBCG::noPGL as control, were used
to track infected cells. Since aerosol infection is suspected
for M. leprae transmission (5, 47) we chose the intranasal
route to administer bacteria, Syk inhibitor, or vehicle controls.
Moreover, CD11b -component of CR3- that is overexpressed
by inflammatory mouse and human alveolar MPs (48, 49)
may represent an important target of PGL-I in vivo. Twenty-
four hours post-infection, cells from the lung parenchyma or
bronchoalveolar lavage (BAL) were harvested and analyzed by
flow cytometry for infection of Ly-6G+, CD11c− PMNs and
Ly-6G−, CD11c+ cells that were mostly alveolar MPs (50)
(see Supplementary Figures S4A–E for gating strategy) in lungs
(Figure 6A), or BAL (Figure 6B). Neither Syk inhibition, nor
CR3 deficiency impacted the number of PMNs or MPs recruited
to the lung (Supplementary Figures S4C,F). However, a higher
incidence of infected PMNs and MPs was detected after infection
with rBCG::PGL-I as opposed to rBCG::noPGL, showing the
enhancing effect of PGL-I on mycobacterial phagocytosis by host
cells in vivo. On the contrary, in PMNs and MPs harvested from
the lungs of itgam−/− mice, the frequencies of rBCG::noPGL
and rBCG::PGL-I uptake were similar. Furthermore, entry of
rBCG::PGL-I into PMNs and MPs in mice receiving the Syk
inhibitor was comparable to mice infected with rBCG::noPGL.
These data confirmed in vivo the key roles of (i) PGL-I in
targeting CR3 and (ii) the involvement of the Syk pathway to
allow operational CR3-mediated entry into myeloid lung cells.
We then measured IL-10 in BAL (Figures 6C,D), where PMNs
were the most abundant (Supplementary Figure S4F). In WT
mice infected with rBCG::PGL-I, IL-10 production was 2.9-times
more elevated than in mice receiving rBCG::noPGL (Figure 6C).
In contrast, both strains induced similar levels of IL-10 in BAL
from itgam−/− mice, or mice treated with the Syk inhibitor.
The enhanced production of IL-10 in BAL of rBCG::PGL-
I-infected mice thus likely reflects increased phagocytosis by
PMNs, leading to CR3-mediated activation of the Syk signaling
cascade. To evaluate the role of NFATc in this process, we
treated WT mice with two doses of CsA 1 h before and 1 h after
inhalation of rBCG::PGL-I or rBCG::noPGL and measured IL-
10 produced in BAL 24 h later (Figure 6D). As expected, we
observed higher levels of IL-10 in BAL from mice infected with
rBCG::PGL-I, as compared to rBCG::noPGL. However, treating
rBCG::PGL-I -infected mice with CsA reduced IL-10 produced
in BAL to levels comparable to rBCG::noPGL-infected mice,
indicating that NFATc translocation is involved in PGL-1-driven
enhanced production of IL-10 (see Figure 6B). Together, these
data confirmed the ability of PGL-I to target CR3 for potent
phagocytosis by PMNs and MPs in vivo, resulting in activation
of the Syk/calcineurin/NFATc pathway and enhanced production
of IL-10 by PMNs.
DISCUSSION
We discovered that production of the lipid virulence factor
PGL-I endows M. leprae and recombinant BCG with the
unique capacity to engage CR3 for potent phagocytosis in three
major subsets of innate cells: DCs, PMNs, and MPs (Figure 7).
This efficient phagocytosis resulted in Syk-dependent NFATc
translocation to the nucleus that rewired cells to produce a
NFATc-specific signature of soluble mediators including IL-2 by
DCs, IL-10 by PMNs, IL-1β by MPs and PGE2 by the three cell
types. This Syk and NFATc biological signature was also observed
in response to native irradiatedM. leprae and in vivo in the lungs
of mice after intranasal infection with rBCG::PGL-I. In addition
to our previous findings on the key ability of PGL-I-producing
mycobacteria to disable TLR2 (18) and TLR4 (19) pathways, our
present findings highlight a newly discovered NFATc pathway,
efficiently triggered by PGL-I engaging CR3, as an additional
weapon that M. leprae uses to fine tune the host response.
Indeed, the NFATc family of transcription factors has long been
recognized as central to T-cell development and functions (51).
It is one of the most important targets to control rejection of
solid organs allografts. NFATc triggering appeared more recently
as a key regulator of both pro and anti-inflammatory processes
(52) governed by innate cells. It’s considered a hallmark of
successful initiation of innate responses to particulate antigens
(53). NFATc translocation is controlled by the Ca2+/calmodulin
phosphatase calcineurin that responds to intracellular increases
in Ca2+ upon formation of the phagocytic synapse in MPs and
DCs. This occurs when particles are engulfed and allows innate
cells to distinguish microbes from soluble compounds to trigger
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FIGURE 4 | PGL-I targeting of CR3 triggers nuclear translocation of NFATc2 downstream of Syk that controls a specific mediator signature. (A,B) IL-2 produced in
DCs supernatants, IL-10 in PMNs and IL-1β in MPs were measured by ELISA and (C) PGE2 by competition ELISA after overnight incubation the three recombinant
(Continued)
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FIGURE 4 | BCG strains at MOI of 5. Data are presented as mean ± SEM. **P < 0.01; ***P < 0.001. (A) Phagocytosis was blocked by treatment for 1 h before
infection with 1 or 50 nM of CytoD, while controls received only the vehicle DMSO (n = 8). (B) Cells were treated with two NFATc inhibitors tacrolimus (FK506, 500
pg/ml) or Cyclosporin (CsA, 50 ng/ml) 1 h before infection by the three rBCG strains. Controls received DMSO (n = 4). (C) For PGE2 production, cells were derived
from bone marrow of WT or itgam−/− mice. (D) Translocation of NFATc2 (green) into the nucleus of MPs (blue, DAPI staining) derived from bone marrow of WT or
itgam−/− mice was analyzed by confocal microscopy 30min after infection with rBCG::PGL-I or rBCG::noPGL at MOI of 5. Cells on slides were then fixed,
permeabilized and stained with anti-NFATc2 and mounted in medium containing DAPI. Images were acquired with a confocal Leica TCS SP8 microscope, where
NFATc2 colocalization with the nucleus appeared in light blue, while NFATc2 remaining in the cytosol appeared in green. Images are from original magnification ×63.
(E) After analysis of images (Image J software) the Manders coefficient was determined with the JACoP (26) plugin that allowed to quantify colocalization of NFATc2
with the nucleus (light blue). These coefficients were calculated in 10 fields from 4 slides (obtained from 2 independent experiments). Box and whisker plot shows
median ± SEM. ***P < 0.001 (Student’s t-test). (F) Cytokine production measured as in (A,B) from WT or itgam−/− cells stimulated with rBCG::PGL-I at MOI of 5 or
γ-irradiated M. leprae (strain NHDP, equivalent to MOI of 10). WT cells received treatment with DMSO or Syk inhibitor GS-9973 or CsA to block NFATc translocation,
1 h before contact with bacteria. Data are presented as mean ± SEM. **P < 0.01; ***P < 0.001.
FIGURE 5 | rBCG::PGL-I preferentially triggers Syk/calcineurin/NFATc through CR3 to rewire innate cells (A) DCs or PMNs from WT or myd88−/− mice were infected
with the three rBCG strains at MOI of 5. WT cells were treated with GS-9973 to inhibit the Syk pathway, or CsA to block NFATc translocation 1 h before infection. After
overnight incubation supernatants were harvested to measure by ELISA IL-2 produced by DCs and IL-10 produced by PMNs. (B) Before infection of DCs or PMNs
with rBCG::noPGL or rBCG::PGL-I as in (A), cells were either incubated for 1 h with anti-CD11b antibody M1/70 to block CR3-mediated entry, or exposed to CsA to
block NFATc translocation as indicated. IL-2 produced by DCs and IL-10 by PMNs after overnight incubation were measured by ELISA. Data are presented as mean
± SEM (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001.
an appropriate antimicrobial cell response (40). This important
checkpoint was discovered with non-opsonic phagocytosis of β-
glucans particulate forms upon binding of the receptor Dectin-
1 (40). We observed that Dectin-1 deficiency in DCs, PMNs,
and MPs (32) resulted in decreased BCG phagocytosis. However,
this was independent of PGL production. For their part, PGLs
modulated infectivity upon binding of the complement receptor
CR3. Remarkably, rBCG::PGL-I infectivity under non-opsonic
conditions was as efficient as after opsonizing with complement.
During Candida albicans infection Dectin-1 is involved in inside-
out signaling that activates CR3 to engage phagocytosis by PMNs
(54). Our data show effective collaboration between these two
receptors for phagocytosis of rBCG::PGL-I. We propose that
Dectin-1—and possibly other CLRs- deliver the first signal for
phagocytosis independently of PGL. Then, binding of the sugar
moiety of PGL-I to activated CR3 reinforces the phagocytic
synapse that efficiently triggers NFATc nuclear translocation.
The signaling pathway leading to nuclear NFATc translocation
is controlled by the pleiotropic hub Syk. During mycobacterial
infection, the Syk-CARD9 pathway is essential to control
bacilli multiplication and overwhelming inflammation (55).
Syk controls cytokine genes transcription via activation of
the canonical NF-κB pathway below recruitment of the
CARD9/BCL-10/MALT1 complex. For mycobacteria Syk is
triggered by the C-type lectin Mincle targeted by the cord
factor, by Dectin-1 recognizing unknown ligands (33) and
potentially by others such as Dectin-2, Mcl, or DCAR. It was
recently discovered that IL-2 production by DCs (40, 43),
and IL-10 by PMNs (41), involves Syk-dependent elevation of
Ca2+ through action of PLCγ that leads to NFATc nuclear
translocation. While depending on Syk, this cascade does not
lead to association with CARD9 and is also different from TLR
signaling. Thus, Syk/NFATc induces a different transcriptional
program compared to the Syk/NF-κB, or MYD88/NF-κB pro-
inflammatory programs (56). So far, activation of NFATc was
only reported when fungi, or particulate β-glucans signal through
Dectins (40, 43), and LPS through CD14 (57). We identified the
lectin-receptor CR3 as another trigger of NFATc translocation
to the nucleus when engaged by PGL-I-bearing mycobacteria.
Accordingly, we observed dramatically reduced IL-2 production
by DCs and IL-10 by PMNs upon blockade of NFATc by
tacrolimus or CsA. Zhang et al. previously reported that
coactivation of Syk and MYD88 was necessary to allow IL-10
production by PMNs infected with BCG, or the M. tuberculosis
H37Rv lab strain (36). We observed that Syk-controlled NFATc
translocation triggered by PGL-I-producing mycobacteria, could
also induce IL-10 production by PMNs and IL-2 by DCs
independently of MYD88. We observed that NFATc blockade
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FIGURE 6 | rBCG::PGL-I targeting CR3 triggers Syk and NFATc in vivo. (A,B) WT and itgam−/− mice were nasally infected with 5 × 106 CFUs of fluorescent
rBCG::PGL-I or rBCG::noPGL, and received two nasal doses of Syk inhibitor GS-9973 administered 1 h before and after bacteria. BAL and lung tissues were
harvested 24 h later to analyze cells by flow cytometry. (A,B) Numbers of Ly-6G+, CD11c− PMNs and Ly-6G−, CD11c+ MPs harboring BCG-EGFP+ recovered from
the lung parenchyma from 11 individuals (A) or BAL from 12 individuals pooled per 2 (B). (C) IL-10 produced in situ by lung cells was analyzed by ELISA in the first
BAL from 12 individuals pooled per 2. (D) WT mice received two nasal doses of CsA 1 h before and 1 h after rBCG::PGL-I or rBCG::noPGL inhalation, to block NFATc
translocation. IL-10 produced in situ by lung cells was analyzed as in (C). Data are represented as individual values from n = 11 (A) or n = 6 (B–D) from two
independent experiments. **P < 0.01; ***P < 0.001.
dramatically reduced IL-1β production by rBCG::PGL-I, or
M. leprae-infected MPs. IL-1β is a biomarker of immune
exacerbations in leprosy (58). Interestingly, IL-1β production
by MPs and DCs in response to Candida albicans signaling
through Dectin-1 is regulated by Syk at two levels: transcriptional
activation of pro-IL-1β and recruitment of the inflammasome
via ROS and potassium eﬄux to produce mature IL-1β (38).
Our data linking efficient CR3-mediated phagocytosis of M.
leprae, or BCG producing PGL-I, and NFATc translocation to
heighten production of IL-1β by MPs brings to the forefront a
new regulatory mechanism. Although, we observed that Syk and
CR3 regulated transcription of the il-1b gene, we did not rule
out that NFATc translocation also regulated the inflammasome
to produce mature IL-1β, which would be worth investigating.
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FIGURE 7 | CR3 triggers the Syk/calcineurin/NFATc pathway upon engagement by PGL-I-producing mycobacteria to rewire the innate response. rBCG::PGL-I
targets the lectin domain of CR3 on the surface of DCs, PMNs, and MPs. Dectin-1 and CR3 cooperate to induce highly efficient entry of the bacilli. This triggers Syk
for translocation of NFATc to the nucleus and initiates a transcriptional program to generate an NF-κB-independent mediator signature. This preferentially
PGL-I-triggered pathway does not depend on MYD88 even though both cooperate to induce maximum levels of these mediators.
Therefore, our data highlight NFATc translocation to the nucleus,
upon PGL-I targeting CR3 for phagocytosis, as a new pathway
used to rewire the innate response againstM. leprae.
It’s also interesting to note that rBCG::PGL-I and rBCG::PGL-
b are almost identical both in size and structure. They differ
only by three sugars branched to the phenol nucleus of the PGL
molecule (17). Strikingly, this small difference allowed sustained
NFATc translocation, which highlights the key role of PGL-
I in manipulating the innate immune system. PGL-I displays
pleiotropic effects during leprosy infections: it down-modulates
short-term TNF (17, 18) and iNOS (19) production by human
MPs, it allows colonization of peripheral nerves via interaction
with Schwann cells (14) and it initiates nerve damage by
instructing NO producing MPs to patrol axons (16). In addition,
PGLs from other pathogenic mycobacteria recruit growth-
permissive monocytes (59) and allow escape from microbicidal
MPs (60). Our data add a newweapon to this arsenal: by targeting
CR3, PGL-I triggers the Syk/calcineurin/NFATc pathway that
rewires the innate immune response in three major innate cells.
We confirmed in vivo that rBCG::PGL-I allowed highly effective
uptake by lung PMNs and MPs provided that CR3 was present
and Syk active. Moreover, high levels of IL-10 were produced by
lung cells infected with rBCG::PGL-I only when CR3 was present
and this was abolished by NFATc inhibition. The lung must be
considered as a portal of entry for the leprosy bacillus, since
leprosy patients release contaminated droplets in nasal secretions
that can be inhaled by contacts (5) and M. leprae interacts
with epithelial lung cells that results in uptake by alveolar MPs
and infection of the lung tissue in the mouse model (47).
Interestingly, resident alveolar MPs upregulate CR3 expression
under inflammatory conditions (48), which would also facilitate
targeting by PGL-I uponM. leprae inhalation.
Thus, what could be the biological impact of NFATc nuclear
translocation in the three major innate cells involved in
modulation of the complex spectrum of the immune response to
M. leprae (7)? During fungal infections PMNs rely on the NFATc
pathway to efficiently kill pathogens and resolve inflammation
through IL-10 production (41). In DCs, NFATc-induced IL-2
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is essential to regulate DC half-life and avoid overwhelming
inflammation (57) and CD103+ lung DCs, producing IL-2
via the NFATc pathway, regulate the local Th17 inflammatory
response (42). In MPs, NFATc is retained in the cytosol by
the kinase LRRK2 and Lrrk2−/− mice develop severe colitis
due to overwhelming inflammation upon NFATc translocation
to the nucleus (61). Interestingly, leprosy patients carrying a
Lrrk2 missense variant are more prone to develop T1R with
excessive inflammation (62) of which IL-1β is one biomarker
(58). Our data that illustrate PGL-I/CR3 binding and NFATc
translocation to generate high production of IL-1β by MPs
could contribute to deciphering how excessive inflammation
in severe leprosy takes place. NFATc also controls COX-2
expression leading to eicosanoid PGE2 production (45). We
observed high levels of PGE2 production by DCs, MPs and
PMNs upon infection with rBCG::PGL-I that was dependent
of CR3 in agreement with efficient NFATc translocation to the
nucleus. PGE2 can play both pro- or anti-inflammatory roles
in leprosy depending on the clinical form (63). High levels of
PGE2 secreted by Schwann cells and foamy MPs in LL may
play an important role in Tregs induction. On the other hand,
COX-2 is highly expressed in vessels and nerves of leprosy
patients suffering from reversal reactions (64). IL-10 is abundant
in lesions from LL patients and induces a specific phagocytic
program by MPs (8). We showed that in mice PMNs were
important cells for IL-10 production upon M. leprae surrogate,
or native strain entry via CR3 and NFATc translocation to
the nucleus. Whether PMNs are involved in rewiring the MP
response in leprosy lesions would be interesting to determine. IL-
10 is also highly detected during LL and is produced by Tregs
and type 2 MPs (4). DCs producing IL-2 are known drivers
of Tregs (65). Our data show that DCs highly upregulate IL-
2 after M. leprae infection and NFATc translocation indicates
that this pathway could also play a role in Treg induction
in LL.
Leprosy ranks second in the order of human mycobacterial
diseases and remains a threat in developing countries despite
costly multidrug therapies programs. Management of reactions
is crucial in preventing sensorimotor dysfunction in leprosy
patients. In this respect, corticosteroids are recommended to
relieve pain, inflammation and reversal of nerve damage (2)
and thalidomide is highly effective to treat ENL (66). However,
these treatments are hampered by side-effects including the
disastrous teratogenic effects for thalidomide. Our work
brings to the forefront NFATc as an important player in
tuning the innate immune response to M. leprae. PGL-I
that triggers this pathway upon CR3 binding, sustains IL-1β
production by MPs that is coordinately regulated with PMN
infiltration in ENL patients (67). Through IL-2 production
by DCs sustaining Tregs (65) and PGE2 synthesis by MPs
(63), NFATc translocation could also explain defective bacilli
control in LL (68). Therefore, our work together with
genetic profiling of leprosy patients (62) could help refine
treatment of inflammatory reactions in leprosy by using
NFATc blockers such as CsA (69) that have a long clinical
track-record. This could improve quality of life of patients
who develop intolerance to steroids and contribute to the
global effort in preventing leprosy-associated disabilities in
vulnerable populations.
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